Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SCYNEXIS's change in inventory for the quarter that ended in Jun. 2026 was €0.00 Mil. It means SCYNEXIS's inventory
stayed the same
from Mar. 2026 to Jun. 2026 .
SCYNEXIS's change in inventory for the fiscal year that ended in Dec. 2025 was €0.00 Mil. It means SCYNEXIS's inventory
stayed the same
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
SCYNEXIS's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.00.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
SCYNEXIS's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS Change In Inventory Related Terms
SCYNEXIS Change In Inventory Historical Data
* Premium members only.
The historical data trend for SCYNEXIS's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of €0.00 Mil mean?
SCYNEXIS (FRA:135) has a Change In Inventory of €0.00 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for SCYNEXIS and its competitors.
Is SCYNEXIS's Change In Inventory too high?
SCYNEXIS's current Change In Inventory is €0.00 Mil. Overall, SCYNEXIS has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's Change In Inventory compare to IXHL and ETST?
SCYNEXIS's Change In Inventory of €0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Drug Manufacturers company?
A good Change In Inventory depends on the Drug Manufacturers industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for SCYNEXIS and its competitors. SCYNEXIS's current Change In Inventory is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
SCYNEXIS (FRA:135) has a current Change In Inventory of €0.00 Mil. The stock's GF Value™ is €14.60, compared to a current price of €4.36 — trading 70.2% below its estimated fair value. The current Change In Inventory is €0.00 Mil. SCYNEXIS's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For SCYNEXIS (FRA:135), the current Change In Inventory is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SCYNEXIS (FRA:135) Overvalued in 2026?
Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued.
The current stock price of €4.36 is trading 70.2% below its estimated GF Value™ of €14.60.
Key valuation signals for FRA:135:
Change In Inventory: €0.00 Mil
GF Value™: €14.60 vs. price of €4.36 (70.2% below fair value)
No single metric tells the full story. See the FRA:135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
40GF Score
Get the complete analysis for FRA:135
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:135 has been successfully added to your 
